LIVE POLIO IRUS VACCINES

628 Index
Serological response-continued
conversions to detect missed infections, 160
evaluation, 454
in children fed CHAT and Fox, 530
in infants of vaccinated mothers, 326
low level, transient in nature, 160
virus isolate and CHAT, 469
Seronegatives
antibody demonstration CPE, pH and IIT tests, 231
distribution by age, 566
for Type 1 poliovirus, 559
prevaccination, estimated number, 391-393
Seronegative conversion rate
and recovery of vaccine, 368
low for seven day interval feeding, 365
Seronegative index
described, advantages and uses, 367, 369
Serum
pathway of infection plotted, 7
Serum hepatitis
tolerance study feasible, 328
Shelokov, Alexis, paper 569-573; 575
Shirman, G. A., paper 413-428
Siblings
desire to minimize contact infection, 309
under 5 kept as susceptibles, 174
Sickle, see Poliomyelitis virus, Type 1, Sickle
Side effects, see Reactions
Sigel, M. Michael, paper 435-444; 439, 456
Silva, M. Martins da, see Martins da Silva, M.
Simian virus
detection in monkey-kidney cultuires, 79-85
human muhltiplication question, 88
in inactivated vaccines, produce immunity, 594
measles-like destroyed by chloroform and ether,
86-87
problem in production and control, 601
susceptibility of newborn animals, 328, 329
types described, 79, 86
vacuolating virus recovered from seed stocks, 80
Simultaneous feeding
interference overcome by dose-size, 8
Type 3 domination, 298
Sinclair-Smith, Dr. - (from East London, Union of
South Africa), 475
Singapore
ambiguous results of trial, 6
large-scale vaccination, 193, 199
Sabin vaccine tested, 580
Sinyak, K. M., paper 413-428
Sister Elizabeth Kenny Foindation, 4, 605
Sitnek, Jane, 292
SK-50, see Poliomyelitis virus, Type 2. SK-50
Skovránek, Vilém. paper 507-521; 371, 506, 532
Skrídlovská, E., paper 228-239
SM, see Vaccine, Attenuated: Type 1 SM (Lederle-
Cox), Type 1 SM (Koprowski)
Smadel, J. E., 158-159, 429, 596, 599
Smallpox
compulsory vaccination, 497
eradication problem, 4, 158, 577, 603
Smallpox-continued
study in Madras, India, 598
vaccine use, 8, 100
Smith, Sinclair, see Sinclair-Smith
Smorodintsev, A. A., paper 482-501, 576-587; 7, 8, 46-
47, 49, 50, 143, 430, 432, 481, 505-506, 576,
579-580
Socio-economic conditions
Aland archipelago, 534
and ecological behavior of polio, 603
and spread rate, 7, 158
for successful immunization, 578
Socio-economic groups
and Salk experience, 592
Cincinnati, 591
Minnesota, 461
polio incidence by, 375
Puerto Rican, 315
vaccinees, controls from same, 411
Sodium chloride
elution study, 42-44
in d marker study, 45
Sodium hydroxide
pH adjustment of fecal samples, 310
Sodium pentobarbital
monkeys anesthetized, 94
Sokolova, I. S., paper 413-428
Soper, Fred L., 598
Sottunga island, Finland
field trial, 533-546
immunity status, 541, 543
Soulth Africa, Union of, 474
incidence by economic groups, 159
South African Health Department
trial feeding and impending epidemic, 475
South African Institute for Medical Research, 474
Soviet Union
area statistics, 581
detail limited on epidemiological surveillance, 445
field trial, 240-265, 413-428, 576-587
no polio cases attributable to vaccine, 420
vaccination statistics, 143, 577
Soviet Union organizations
Academy of Medical Sciences, USSR, 413, 432,
581-582
Ministry of the Union Republic
decree, reporting of polio cases, 486
USSR Ministry of Health, 432, 485, 580
decree, immunization of population between 2
months and 20 years, 413, 582
Spread
among contacts, 577
and controlled evaluation of effectiveness, 157
and fecal excretion of virus. 160
by economic status, and Salk vaccination, 158, 597
by type, 115, 163, 538, 542, 562
characteristic of live vaccine, 485
children less than 2 years, 187, 202
conditions necessary, listed, 7
during siummer, 172
from newborns, 197, 199, 223
inadvertent polio-imiiiiunization benefit, 172